Goodrx Holdings, Inc. valuation and forecast
Explore the models for Goodrx Holdings, Inc., adjust their assumptions and compare your own valuation with the platform's.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: share count (348m) is 3.2x the market-data count (107m).
Price vs value
Under review: share count (348m) is 3.2x the market-data count (107m). We'll show the comparison once resolved.
Analyst recommendations
Monthly trend
- Oct 202614
- Sep 202614
- Aug 202615
- Jul 202615
Counts of recommendations published by analysts covering Goodrx Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.
Price history
Loading chart…
Third-party market data · may be delayed
The assumptions
- Free cash flow (TTM, FY2026 Q2)
- $197M
- Less stock-based pay
- $75.9M
- Cash flow we value
- $111M
- Growth, years 1–5 (base)
- %
- Then fading to
- 2.5%
- Discount rate
- 8.5%
- Net cash added
- -$190M
- Diluted shares
- 348M
What would move the value
- Growth 5 points lower
- −27%
- Growth 5 points higher
- +35%
- Free-cash-flow margin 1 point lower
- −4%
- Discount rate 1 point higher
- −15%
Change in our model value when one input moves, all else equal.
GDRX valuation questions
- How does Fundamentalytics value Goodrx Holdings, Inc.?
- We use the models that fit Goodrx Holdings, Inc.'s business and available financial data: cash-flow model (dcf), forward price-to-earnings vs peers. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.
Data: SEC EDGAR filings, retrieved October 29, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Goodrx Holdings, Inc.